Evidence map›Paper›PMID 39641537›Full record

ArticleJournal of comparative effectiveness research2025

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Whitney S GraybillDivision of Gynecologic Oncology, Medical University of South Carolina, Charleston, SC 29425, USA.
Ignace VergoteUniversity Hospitals Leuven, Leuven Cancer Institute, and Belgium & Luxembourg Gynaecological Oncology Group (BGOG), Leuven, B912 3000, Belgium.
Bhavana PothuriGOG Foundation and Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA.
Maarit AnttilaKuopio University Hospital, Kuopio, Finland, and NSGO, Copenhagen, 9 70200, Denmark.
David M O'MalleyThe Ohio State University andthe James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Domenica LorussoHumanitas San Pio X, Milan, Humanitas University, Rozzano, 20089, Italy.
Ashley F HaggertyHackensack Meridian Health, Hackensack, NJ 07601, USA.
Michel FabbroInstitut Régional du Cancer de Montpellier, Montpellier, and GINECO, Paris, 34298, France.
John K ChanCalifornia Pacific Medical Center Palo Alto Medical Foundation, Sutter Cancer Research Consortium, San Francisco, CA 94301, USA.
Florian HeitzAGO Study Group and Kliniken Essen-Mitte, Essen, and Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, 12203, Germany.
Lyndsay J WillmottArizona Center for Cancer Care, Phoenix, AZ 85027, USA.
Ilan BruchimHillel Yaffe Medical Center, Hadera, Technion Institute of Technology, Haifa, 38100, Israel, & ISGO.
Ying ZhuoKadlec Hematology and Oncology Clinic, Richland, WA 99336, USA.
Purificación Estévez-GarcíaHospital Universitario Virgen del Rocío, Sevilla, and GEICO, Madrid, 41013, Spain.
Bradley J MonkGOG Foundation; Florida Cancer Specialists and Research Institute, West Palm Beach, FL 33401, USA.
Hannelore DenysGhent University Hospital, Ghent, 9000, Belgium.
Anja KnudsenOdense University Hospital, Odense, 5000, Denmark.
Anna V TinkerBC Cancer Vancouver, and Department of Medicine, University of British Columbia, Vancouver, BC, V6T1Z1, Canada.
Luis Manso SánchezHospital Universitario 12 de Octubre & GEICO, Madrid, 28041, Spain.
Diane ProvencherCentre Hospitalier de l'Université de Montréal, Université de Montréal and Institut du Cancer de Montréal, Montreal, QC, H3T1J4, Canada.
Maria Pilar Barretina-GinestaMedical Oncology Department, Institut Català d'Oncologia; Girona Biomedical Research Institute (IDIBGI-CERCA), Girona University, Girona, Spain, and GEICO, 08908, Spain.
John HartmanGSK, Philadelphia, PA 19112, USA.
Donna V BoothGSK, Durham, NC 27709, USA.
Antonio González-MartínMedical Oncology Department, Program in Solid Tumours, CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, and Grupo Español de Investigación en Cancer ginecológicO (GEICO), Madrid, 28027, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IndazolesOvarian NeoplasmsPiperidinesFemaleHematologic DiseasesHumansPoly(ADP-ribose) Polymerase InhibitorsUnited StatesIndazolesniraparibPiperidinesPoly(ADP-ribose) Polymerase Inhibitorscost managementmaintenance therapyniraparibovarian cancerPARP inhibitor

Identifiers

PMID39641537
PMCPMC11656343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.